• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report.

作者信息

Dell'Unto Elisabetta, Rinzivillo Maria, Esposito Gianluca, Iannicelli Elsa, Prosperi Daniela, Panzuto Francesco, Annibale Bruno

机构信息

Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy.

Digestive Disease Unit-ENETS Center of Excellence, Sant'Andrea University Hospital, Italy.

出版信息

Gastroenterol Rep (Oxf). 2024 Apr 16;12:goae023. doi: 10.1093/gastro/goae023. eCollection 2024.

DOI:10.1093/gastro/goae023
PMID:38634006
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11021807/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4fc/11021807/bfd4a5bcbfc8/goae023f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4fc/11021807/bfd4a5bcbfc8/goae023f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4fc/11021807/bfd4a5bcbfc8/goae023f1.jpg

相似文献

1
Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report.一名年轻成人转移性1型低级别胃神经内分泌肿瘤接受肽受体放射性核素治疗：病例报告
Gastroenterol Rep (Oxf). 2024 Apr 16;12:goae023. doi: 10.1093/gastro/goae023. eCollection 2024.
2
Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?钇 90 选择性内放射治疗与肽受体放射性核素治疗在转移性神经内分泌肿瘤中的应用：联合还是不联合？
Nucl Med Commun. 2020 Dec;41(12):1242-1249. doi: 10.1097/MNM.0000000000001284.
3
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.德国肽受体放射性核素治疗神经内分泌肿瘤的有效性和副作用：一项具有前瞻性随访的多机构登记研究
Eur J Cancer. 2016 May;58:41-51. doi: 10.1016/j.ejca.2016.01.009. Epub 2016 Mar 2.
4
Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.奥曲肽受体显像在非(131)I 摄取的转移性分化型甲状腺癌中评估(177)Lu-DOTATATE 肽受体放射性核素治疗的可行性：适合肽受体放射性核素治疗的患者比例较低，且存在嗜铬粒蛋白 A 水平阳性神经内分泌分化的证据。
Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429.
5
Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report.肽受体放射性核素治疗成功治疗晚期转移性胰腺神经内分泌肿瘤：病例报告
Explor Target Antitumor Ther. 2022;3(3):392-397. doi: 10.37349/etat.2022.00089. Epub 2022 Jun 29.
6
Safety and efficacy of peptide receptor radionuclide therapy with Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors.肽受体放射性核素治疗 Lu-DOTA-EB-TATE 治疗转移性神经内分泌肿瘤患者的安全性和疗效。
Theranostics. 2022 Sep 6;12(15):6437-6445. doi: 10.7150/thno.77219. eCollection 2022.
7
Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies.转移性神经内分泌肿瘤患者接受肽受体放射性核素治疗的缓解率及对未来治疗策略的影响。
Surgery. 2021 Jan;169(1):162-167. doi: 10.1016/j.surg.2020.04.001. Epub 2020 May 20.
8
Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients.了解转移性胰腺神经内分泌肿瘤患者的治疗算法：一项单机构回顾性分析，比较255例患者化疗、分子靶向治疗和肽受体放射性核素治疗的结果。
Neuroendocrinology. 2021;111(9):863-875. doi: 10.1159/000511662. Epub 2020 Sep 18.
9
Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.镥 177 标记的奥曲肽治疗神经内分泌肿瘤肝转移患者后行钬 166 放射性栓塞术（HEPAR PLuS）：一项单中心、单臂、开放标签、2 期研究。
Lancet Oncol. 2020 Apr;21(4):561-570. doi: 10.1016/S1470-2045(20)30027-9. Epub 2020 Feb 26.
10
Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.用¹⁷⁷镥-奥曲肽对表达生长抑素受体的神经内分泌肿瘤患者进行肽受体放射性核素治疗：六年评估
Clin Nucl Med. 2017 Jun;42(6):436-443. doi: 10.1097/RLU.0000000000001629.

本文引用的文献

1
Endoscopic management of gastric, duodenal and rectal NETs: Position paper from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Society of Gastroenterology (SIGE), Italian Society of Digestive Endoscopy (SIED).胃、十二指肠和直肠神经内分泌肿瘤的内镜治疗：意大利神经内分泌肿瘤学会（Itanet）、意大利胃肠病学会（SIGE）和意大利消化内镜学会（SIED）的立场文件。
Dig Liver Dis. 2024 Apr;56(4):589-600. doi: 10.1016/j.dld.2023.12.015. Epub 2024 Jan 11.
2
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3.欧洲神经内分泌肿瘤学会（ENETS）2023 年胃十二指肠神经内分泌肿瘤（NETs）G1-G3 指导意见。
J Neuroendocrinol. 2023 Aug;35(8):e13306. doi: 10.1111/jne.13306. Epub 2023 Jul 4.
3
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lu-Dotatate 联合长效奥曲肽与高剂量长效奥曲肽治疗肠神经内分泌肿瘤患者（NETTER-1）：一项开放标签、随机、对照、III 期临床试验的最终总生存和长期安全性结果。
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
4
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study.肿瘤类型和大小是胃神经内分泌肿瘤的预后因素：一项多中心回顾性研究。
Dig Liver Dis. 2019 Oct;51(10):1456-1460. doi: 10.1016/j.dld.2019.04.016. Epub 2019 Jun 5.
5
Long-Term Efficacy, Survival, and Safety of [Lu-DOTA,Tyr]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.《[Lu-DOTA,Tyr]octreotate 治疗胃肠胰和支气管神经内分泌肿瘤患者的长期疗效、生存和安全性》。
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.
6
Gastric cancer in patients with type I gastric carcinoids.I型胃类癌患者的胃癌
Gastric Cancer. 2015 Jul;18(3):564-70. doi: 10.1007/s10120-014-0393-8. Epub 2014 Jun 3.
7
Metastatic type 1 gastric carcinoid: a real threat or just a myth?胃 1 型类癌转移：是真实的威胁还是仅仅是个传说？
World J Gastroenterol. 2013 Dec 14;19(46):8687-95. doi: 10.3748/wjg.v19.i46.8687.
8
Systematic review: gastric cancer incidence in pernicious anaemia.系统评价：恶性贫血患者胃癌发病率。
Aliment Pharmacol Ther. 2013 Feb;37(4):375-82. doi: 10.1111/apt.12177. Epub 2012 Dec 10.
9
Unusually aggressive type 1 gastric carcinoid: a case report with a review of the literature.不典型侵袭性 1 型胃类癌：病例报告并文献复习。
Eur J Gastroenterol Hepatol. 2012 May;24(5):589-93. doi: 10.1097/MEG.0b013e328350fae8.
10
Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type.胃类癌：不同类型分化治疗后的生物学行为及预后
Ann Surg. 2005 Jul;242(1):64-73. doi: 10.1097/01.sla.0000167862.52309.7d.